FDA
-
-
-
-
-
-
-
Bioventus receives FDA clearance for two nerve stimulation devices
-
-
-
-
-
-
-
Bioventus Reports Second Quarter Financial Results
-
-
-
-
-
-
-
Bioventus Announces Divestiture of its Wound Business
-
-
-
-
-
-
-
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
-
-
-
-
-
-
-
Bioventus (BVS) Reports Prelim Q1 Sales of $116.5M-$118.5M, Adjusted EBITDA of ($19.4M)-($19M)
-
-
-
-
-
-
-
Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device
-
-
-
-
-
-
-
Bioventus (BVS) Granted US FDA Clearance for BoneScalpel Access
-
328,513 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

